LivaNova PLC $LIVN Shares Sold by Nordea Investment Management AB

Nordea Investment Management AB cut its holdings in LivaNova PLC (NASDAQ:LIVN) by 12.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 92,258 shares of the company’s stock after selling 12,955 shares during the quarter. Nordea Investment Management AB’s holdings in LivaNova were worth $5,689,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of LivaNova by 4.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,497 shares of the company’s stock worth $1,394,000 after buying an additional 1,360 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in LivaNova by 4.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 814,974 shares of the company’s stock valued at $32,012,000 after acquiring an additional 36,094 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in LivaNova by 10.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 168,863 shares of the company’s stock worth $6,633,000 after acquiring an additional 15,405 shares during the period. Intech Investment Management LLC lifted its position in LivaNova by 19.6% during the 1st quarter. Intech Investment Management LLC now owns 43,879 shares of the company’s stock worth $1,724,000 after acquiring an additional 7,195 shares during the period. Finally, Strs Ohio purchased a new position in shares of LivaNova in the 1st quarter valued at approximately $130,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

LivaNova Price Performance

Shares of LIVN opened at $63.65 on Friday. The company has a current ratio of 1.36, a quick ratio of 1.16 and a debt-to-equity ratio of 0.29. The stock’s 50 day moving average is $64.91 and its two-hundred day moving average is $60.11. LivaNova PLC has a twelve month low of $32.48 and a twelve month high of $71.92. The firm has a market capitalization of $3.48 billion, a PE ratio of -14.27 and a beta of 0.92.

LivaNova (NASDAQ:LIVN) last issued its earnings results on Wednesday, February 25th. The company reported $0.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.80 by $0.06. The business had revenue of $360.92 million during the quarter, compared to the consensus estimate of $354.31 million. LivaNova had a positive return on equity of 16.54% and a negative net margin of 17.46%.The company’s revenue for the quarter was up 12.2% on a year-over-year basis. During the same period in the prior year, the business posted $0.81 EPS. LivaNova has set its FY 2026 guidance at 4.150-4.250 EPS. Research analysts anticipate that LivaNova PLC will post 2.85 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on LIVN shares. Robert W. Baird set a $75.00 target price on LivaNova in a report on Tuesday, December 16th. KeyCorp started coverage on shares of LivaNova in a research report on Friday, December 19th. They issued an “overweight” rating and a $81.00 price objective on the stock. Wall Street Zen raised shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 20th. Piper Sandler reissued an “overweight” rating and issued a $85.00 price objective on shares of LivaNova in a research note on Thursday, February 19th. Finally, Barclays upped their price objective on shares of LivaNova from $67.00 to $73.00 and gave the stock an “equal weight” rating in a research report on Friday, February 27th. Seven analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $74.78.

LivaNova Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.